New combo therapy tested for Tough-to-Treat head and neck cancers

This study is testing a two-drug combination for adults with advanced head and neck cancer that has spread or returned and has gotten worse despite prior immunotherapy. The goal is to see if adding a chemotherapy drug (nab-paclitaxel) to an immunotherapy drug (nivolumab) can shrink tumors and slow the cancer's growth better than past treatments have for similar patients. It is a Phase 2 trial, which means researchers are primarily checking how well the treatment works and monitoring its side effects in a specific group of 46 participants.